Welcome to our dedicated page for Bright Minds Biosciences news (Ticker: DRUG), a resource for investors and traders seeking the latest updates and insights on Bright Minds Biosciences stock.
Bright Minds Biosciences develops highly selective serotonergic agonists for neurological and psychiatric disorders, with programs targeting drug-resistant epilepsy, Prader-Willi Syndrome, depression and other CNS disorders. News about DRUG commonly centers on its 5-HT receptor platform, BMB-101 clinical results in absence seizures and Developmental and Encephalopathic Epilepsies, and pipeline work that includes BMB-105 and earlier-stage new chemical entity programs.
Company updates also include healthcare-conference presentations, scientific meeting participation, public offerings and other capital actions used to support clinical trials, research and development, and general corporate purposes.
Bright Minds Biosciences announced a symposium for May 19, 2022, focusing on updates regarding BMB-101, its lead program for Dravet Syndrome treatment. Key speakers include CEO Ian McDonald and CMO Dr. Revati Shreeniwas. The event will feature expert discussions and a Q&A session. Additionally, the company has issued 60,000 RSUs related to consulting agreements and plans to issue 25,000 common shares, both subject to vesting and hold periods. Dravet Syndrome, affecting approximately 1:15,700 individuals in the U.S., represents a significant unmet medical need.
Bright Minds Biosciences (Nasdaq: DRUG) announced the successful completion of 28-day repeat-dose toxicity studies for its lead product, BMB-101, with no major toxicological findings observed. Conducted by ITR Laboratories Canada, the studies confirmed that BMB-101 was well tolerated in both mice and dogs at doses of up to 40 and 30 mg/kg/day, respectively. The results support the forthcoming first-in-human clinical trial anticipated in Q2 2022. Dr. Revati Shreeniwas noted the potential of BMB-101 as a treatment for Dravet Syndrome, highlighting a significant unmet need in this area.
Bright Minds Biosciences (NASDAQ: DRUG) announced that management will present virtually at the Oppenheimer 32nd Annual Healthcare Conference on March 17, 2022, at 2:00 PM ET. The presentation will focus on the company's work in developing novel treatments for neuropsychiatric disorders, epilepsy, and pain, particularly BMB-101. This selective serotonin agonist shows promise in treating conditions like Dravet syndrome and mental health disorders. An archived version will be available on the company’s website for 90 days post-conference.
Bright Minds Biosciences (BMB) announced a virtual presentation by CEO Ian McDonald and CSO Alan Kozikowski at the H.C. Wainwright Bioconnect Conference on January 10, 2022, starting at 7:00am ET. The presentation will cover their innovative drug development targeting neuropsychiatric disorders and epilepsy. The company is focused on advancing BMB-101, a selective serotonin receptor agonist, showing potential in treating addiction and impulsive behaviors. A replay of the presentation will be available on their website for 90 days after the event.
Bright Minds Biosciences (BMB) announced CEO Ian McDonald will present virtually at the Stifel GMP 2nd Annual Future of Healthcare Conference on December 8, 2021, at 3:00 PM ET. The conference will feature a webcast, with an archived replay available on the company's website for 90 days. Bright Minds is focused on developing innovative treatments for neuropsychiatric disorders, epilepsy, and pain. Its investigational drug BMB-101 shows promise in treating conditions like Dravet syndrome and mental health disorders by targeting serotonin receptors involving crucial neurotransmitter pathways.
Bright Minds Biosciences (BMBIF, DRUG) announced significant advancements in its 5-HT2A psychedelic drug discovery program. The company has synthesized hundreds of novel compounds and aims to announce its lead molecule by Q1 2022. Utilizing advanced drug design and preclinical modeling, Bright Minds aims to develop safer, more potent treatments for neuropsychiatric disorders, including depression and PTSD. The potential market for mental health drugs is projected to grow from $37 billion in 2020 to $59 billion by 2031, highlighting a significant commercial opportunity for the company.
Bright Minds Biosciences (BMB) announced its common stock will be listed on the Nasdaq Capital Market under the ticker symbol 'DRUG' starting November 8, 2021. This listing is seen as a milestone, aiming to enhance shareholder returns and market presence. The company is advancing its lead drug candidate, BMB-101, targeting Dravet syndrome, with first-in-human trials expected in H1 2022. BMB focuses on innovative treatments for neuropsychiatric disorders, leveraging serotonin agonists to tackle difficult-to-treat conditions.